Online Supplemental Material

Supplemental Table S1. Age Stratified Analysis of Diabetes Specific Risk Factors

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Age1: 18-41** |  | **Age: 42-52** |  | **Age: 53-61** |  | **Age: 62+** |  |
|  | **CVD** | **No CVD** | **OR** | **CVD** | **No CVD** | **OR** | **CVD** | **No CVD** | **OR** | **CVD** | **No CVD** | **OR** |
|  | **N = 74** | **N = 5590** |  | **N = 80** | **N = 1412** |  | **N = 89** | **N = 879** |  | **N = 82** | **N = 521** |  |
| **Duration (yrs)2, 3** | 18 (10) | 14 (8) | 1.81\* | 30 (11) | 25 (12) | 1.37\* | 34 (13) | 28 (14) | 1.47\* | 35 (16) | 29 (15) | 1.25\* |
| **HbA1c3 (%)** | 8.5 (1.8) | 8.1 (1.6) | 1.15 | 8.1 (1.2) | 7.6 (1.2) | 1.28\* | 7.8 (1.5) | 7.6 (1.1) | 1.14 | 7.4 (1.0) | 7.4 (1.0) | 0.98 |
| **Longitudinal HbA1c SD3, 4 (%)** | 0.59 (0.4) | 0.51 (0.5) | 1.31 | 0.48 (0.5) | 0.38 (0.3) | 1.97 | 0.46 (0.4) | 0.37 (0.3) | 2.34\* | 0.37 (0.2) | 0.34 (0.2) | 1.60 |
| **Nephropathy** | 19 (26%) | 445 (8%) | 4.00\* | 31 (39%) | 201 (14%) | 3.81\* | 28 (31%) | 145 (17%) | 2.32\* | 35 (43%) | 148 (28%) | 1.88\* |
| **Microalbuminuria** | 13 (18%) | 314 (7%) | 3.58\* | 12 (15%) | 115 (8%) | 1.99 | 12 (13%) | 58 (7%) | 2.21 | 13 (16%) | 46 (9%) | 1.95 |
| **Macroalbuminuria** | 5 (7%) | 63 (1%) | 6.36\* | 6 (8%) | 26 (2%) | 4.32\* | 2 (2%) | 11 (1%) | 1.81 | 1 (1%) | 5 (1%) | 1.27 |
| **eGFR < 60** | 8 (11%) | 107 (2%) | 5.20\* | 22 (29%) | 101 (8%) | 5.01\* | 20 (23%) | 98 (12%) | 2.22\* | 27 (34%) | 125 (25%) | 1.52 |
| **Autonomic Neuro** | 2 (3%) | 39 (1%) | 3.95 | 7 (9%) | 41 (3%) | 3.21\* | 3 (3%) | 37 (4%) | 0.79 | 3 (4%) | 13 (3%) | 1.49 |
| **Peripheral Neuro** | 4 (5%) | 58 (1%) | 5.45\* | 7 (9%) | 56 (4%) | 2.32 | 5 (6%) | 52 (6%) | 0.95 | 10 (12%) | 36 (7%) | 1.87 |

1. Age groups based on 25th percentile, median and 75th percentile of baseline age among those with CVD

2. OR estimates reported per 10 years.

3. Mean (standard deviation) reported.

4. Standard deviation of HbA1c values taken during registry enrollment.

\*Indicates statistical significance at α = 0.01.

Supplemental Table 2. Analysis of Diabetes Risk Factors by Use of Statin Medications

|  |  |  |
| --- | --- | --- |
|  | **Statin Use** | **No Statin Use** |
|  | **CVD****N=210** | **No CVD****N=2711** | **OR** | **CVD****N=115** | **No CVD****N=5691** | **OR** |
| **Duration (yrs)1,2** | 32 ± 13 | 24 ± 13 | 1.54\* | 26 ± 15 | 15 ± 10 | 2.01\* |
| **HbA1c2** | 7.9 ± 1.3 | 7.8 ± 1.3 | 1.09 | 7.9 ± 1.6  | 8.0 ± 1.6 | 0.96 |
| **Longitudinal HbA1c-SD2,3**  | 0.44 ± 0.38 | 0.41 ± 0.37 | 1.21 | 0.51 ± 0.43 | 0.48 ± 0.46 | 1.11 |
| **Nephropathy** | 81 (39%) | 481 (18%) | 2.91\* | 32 (28%) | 458 (8%) | 4.41\* |
| **Microalbuminuria** | 39 (19%) | 235 (9%) | 2.40\* | 11 (10%) | 298 (5%) | 1.91 |
| **Macroalbuminuria** | 11 (5%) | 56 (2%) | 2.62\* | 3 (3%) | 49 (1%) | 3.06 |
| **eGFR < 60** | 52 (26%) | 273 (11%) | 2.82\* | 25 (23%) | 158 (3%) | 8.38\* |
| **Autonomic Neuro** | 12 (6%) | 73 (3%) | 2.19 | 3 (3%) | 57 (1%) | 2.65 |
| **Peripheral Neuro** | 16 (8%) | 107 (4%) | 2.01 | 10 (9%) | 95 (2%) | 5.61\* |

1. OR estimates reported per 10 years

2. Mean (standard deviation) reported

3. Standard deviation of HbA1c values taken during registry enrollment.

\*Indicates statistical significance at α = 0.01; NS=not significant.